IPINOVYX BIO
IpiNovyx Bio is a biopharmaceutical company developing a platform of best-in-class immunoproteasome modulating therapeutics to transform the treatment of autoimmune and inflammatory diseases.
IPINOVYX BIO
Industry:
Biotechnology
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.ipinovyxbio.com
Status:
Active
Total Funding:
10 M USD
Technology used in webpage:
Wix Hosted
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
IntraBio
IntraBio is a biopharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Viva BioInnovator
Viva BioInnovator investment in Seed Round - IpiNovyx Bio
Patrick Spaulding Ryan Ph.D
Patrick Spaulding Ryan Ph.D investment in Seed Round - IpiNovyx Bio
Alexandria Venture Investments
Alexandria Venture Investments investment in Seed Round - IpiNovyx Bio
Opaleye Management
Opaleye Management investment in Seed Round - IpiNovyx Bio
Orange Grove Bio
Orange Grove Bio investment in Seed Round - IpiNovyx Bio
Lilly Ventures
Lilly Ventures investment in Seed Round - IpiNovyx Bio
Pathway Bioventures
Pathway Bioventures investment in Seed Round - IpiNovyx Bio
Generation Ventures
Generation Ventures investment in Seed Round - IpiNovyx Bio
Official Site Inspections
http://www.ipinovyxbio.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "IpiNovyx Bio"
IpiNovyx Bio | Transforming Proteasome Inhibition for Disease
IpiNovyx Bio is developing best-in-class proteasome inhibitors to treat cancer, autoimmune and inflammatory diseases. Backed by cutting-edge research from Weill Cornell Medicine and the …See details»
About IpiNovyx Bio | Advancing Proteasome Inhibitor Therapies
About IpiNovyx Bio. Our Mission & Vision. Our mission is to develop the next generation of more potent and safer proteasome inhibitors to transform the treatment landscape of treatment for …See details»
IpiNovyx Bio - Crunchbase Company Profile & Funding
IpiNovyx Bio is a biopharmaceutical company developing immunoproteasome-modulating therapeutics to treat autoimmune and inflammatory diseases. It helps create inhibitors to …See details»
IpiNovyx - LinkedIn
IpiNovyx Bio has to-date closed a $10 million seed financing round; alongside Orange Grove Bio, prominent investors include Eli Lilly and Company, Viva BioInnovator, Opaleye Management, and ...See details»
IpiNovyx 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for IpiNovyx. Use the PitchBook Platform to explore the full profile.See details»
IpiNovyx Bio - Funding, Financials, Valuation & Investors
IpiNovyx Bio is a biopharmaceutical company developing immunoproteasome-modulating therapeutics to treat autoimmune diseases. New. Resources. Advanced Search. ... How much …See details»
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical …
Oct 6, 2021 Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry. We are excited to announce our portfolio company, Ipinovyxbio‘s, launch! ... a 501 (c) (3) organization …See details»
IpiNovyx Bio - VentureRadar
IpiNovyx Bio is developing multiple series of highly selective, ultra potent small molecule therapeutics for the treatment of autoimmune and inflammatory disorders. Once validated in …See details»
IpiNovyx - Viva BioInnovator
IpiNovyx Bio is a New York-based biotech company, developing immunoproteasome inhibitors for the treatment of autoimmune diseases. Their leading compounds are highly selective and reversible immunoproteasome …See details»
IpiNovyx Bio | Precision Proteasome Inhibitor Research
At IpiNovyx Bio, our research is driven by a commitment to precision and innovation. We are pioneering the development of next-generation more potent and selective proteasome …See details»
IpiNovyx Bio - Products, Competitors, Financials, Employees ...
IpiNovyx Bio was founded in 2021. Where is IpiNovyx Bio's headquarters? IpiNovyx Bio's headquarters is located at 11 Aberdeen Dr, West Nyack. What is IpiNovyx Bio's latest funding …See details»
IpiNovyx Bio - VentureRadar
IpiNovyx Bio is developing multiple series of highly selective, ultra potent small molecule therapeutics for the treatment of autoimmune and inflammatory disorders. ... Dansk Biotek …See details»
IpiNovyx Bio Inc. - Center For Technology Licensing
IpiNovyx Bio Inc. October 14, 2021 March 15th, 2023. Home » Startups » IpiNovyx Bio Inc. Tweet Share. IpiNovyx is a biopharmaceutical company that aims to transform the ways autoimmune …See details»
IpiNovyx Bio Closes $10 Million Seed Financing to Advance
Oct 5, 2021 IpiNovyx Bio is a drug development and platform technology company focused on novel therapeutics to treat autoimmune and inflammatory diseases through selective inhibition …See details»
Contact IpiNovyx Bio | Get in Touch with Us
Reach out to IpiNovyx Bio for partnership, investment, or general inquiries. Learn more about how we’re transforming healthcare through innovative proteasome therapies.See details»
IpiNovyx Bio Closes on $10 Million Seed Financing Round to …
Oct 6, 2021 IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform “New York-based IpiNovyx Bio announced the closing of a $10 million seed financing …See details»
IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in …
IpiNovyx Bio, a biopharmaceutical company developing a platform of best-in-class immunoproteasome modulating therapeutics to transform treatment of autoimmune and …See details»
Invest in IpiNovyx Bio | Transforming Healthcare Solutions
IpiNovyx Bio is at the forefront of developing innovative therapies for cancer, autoimmune and inflammatory diseases, leveraging our proprietary proteasome modulation platform. With …See details»
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical …
Oct 5, 2021 Eli Lilly is among the investors backing preclinical biotech IpiNovyx Bio as it emerges with $10 million to go after inflammatory and autoimmune diseases.. The New York …See details»
IpiNovyx Bio Closes $10 Million Seed Financing to ... - Pipelinereview
Oct 5, 2021 IpiNovyx Bio is a drug development and platform technology company focused on novel therapeutics to treat autoimmune and inflammatory diseases through selective inhibition …See details»